In effect, even if symptomatic treatments have significantly pushed forward the mean survival age from 6 months (in 1938) to 47 years (in 2000), life quality and expectancy for CF patients still need to be ameliorated, by enriching the therapeutic options and the possibility of personalized therapies (mainly based on the type of CFTR mutation). Here, CFTR is linked to cystic fibrosis.